{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:06:24Z","timestamp":1761894384116},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,7,24]],"date-time":"2006-07-24T00:00:00Z","timestamp":1153699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>  <jats:italic>Objectives<\/jats:italic>:\u2002A potential role in cancer biology is suggested for YKL\u201040 (CHI3L1, HC gp\u201039). The purpose of this study was to evaluate the clinical value of serum YKL\u201040 (sYKL\u201040) in multiple myeloma (MM) and to examine YKL\u201040 expression in malignant plasma cells (MM PCs). <jats:italic>Methods<\/jats:italic>:\u2002sYKL\u201040 was measured by enzyme\u2010linked immunosorbent assay (ELISA) in 82 patients with newly diagnosed MM. YKL\u201040 expression in immunophenotypically defined plasma cells was investigated by double\u2010labelled immunohistochemistry in 21 MM patients and by real\u2010time reverse transcriptase polymerase chain reaction (RT\u2010PCR) in cDNA archives generated by global RT\u2010PCR in seven controls, 14 patients with monoclonal gammopathy of undetermined significance (MGUS), 45 MM patients, nine patients with extramedullary myeloma (exMM), and seven human myeloma cell lines (HMCLs). <jats:italic>Results<\/jats:italic>:\u2002sYKL\u201040 was elevated above a constructed reference range for healthy controls in 29% of the patients investigated. Patients with elevated sYKL\u201040 had reduced overall survival and event\u2010free survival when compared to patients with normal sYKL\u201040, but sYKL\u201040 level was defeated by <jats:italic>\u03b2<\/jats:italic><jats:sub>2<\/jats:sub>\u2010microglobulin in the multivariate analyses. Intramedullary MM PCs lacked significant expression of YKL\u201040, but high levels of YKL\u201040 expression were seen in extramedullary MM PCs from one exMM patient and in six HMCLs. Further investigations of other bone marrow (BM) cells showed YKL\u201040 expression in megakaryocytes, neutrophils and adherent cells from long\u2010term BM cultures. <jats:italic>Conclusions<\/jats:italic>:\u2002In newly diagnosed MM\u2010patients, a sYKL\u201040 elevated above the reference range predicts a poor clinical outcome, and YKL\u201040 is expressed by other BM cells than MM PCs. At this point, routine measurements of sYKL\u201040 are not warranted, but YKL\u201040 should be considered as a potential player in the pathophysiology of MM.<\/jats:p>","DOI":"10.1111\/j.0902-4441.2006.t01-1-ejh2879.x","type":"journal-article","created":{"date-parts":[[2006,8,23]],"date-time":"2006-08-23T11:31:38Z","timestamp":1156332698000},"page":"416-424","source":"Crossref","is-referenced-by-count":26,"title":["Serum YKL\u201040 concentrations in newly diagnosed multiple myeloma patients and YKL\u201040 expression in malignant plasma cells"],"prefix":"10.1111","volume":"77","author":[{"given":"Anne K.","family":"Mylin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia S.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene M.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H.","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig","family":"Lenhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger M. S.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans E.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Nordic Myeloma Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc746"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690238"},{"key":"e_1_2_6_4_2","first-page":"4423","article-title":"High levels of serum HER\u20102\/neu and YKL\u201040 independently reflect aggressiveness of metastatic breast cancer","volume":"9","author":"Jensen BV","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.112"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.05.010"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.11.011"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.251547398"},{"key":"e_1_2_6_9_2","first-page":"4364","article-title":"Gene expression microarray analysis reveals YKL\u201040 to be a potential serum marker for malignant character in human glioma","volume":"62","author":"Tanwar MK","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63875-8"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650070506"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2005.00026.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1765"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2921"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80095-1"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2000.0377"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310000537"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.60.4.540"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1997.3764"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306792200"},{"key":"e_1_2_6_22_2","first-page":"351","article-title":"YKL\u201040, a mammalian member of the chitinase family, is a matrix protein of specific granulas in human neutrophils","volume":"110","author":"Volck B","year":"1998","journal-title":"Proc Assoc Am Physicians"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)74461-5"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.22.13076"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5253"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20020075"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4511"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4827(03)00069-7"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303137200"},{"key":"e_1_2_6_30_2","first-page":"7","article-title":"Impact on survival of high\u2010dose therapy with autologous stem cell support in patients younger than 60\u2003years with newly diagnosed multiple myeloma: a population\u2010based study","volume":"95","author":"Lenhoff S","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.6.553"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04577.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01770.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.8.4756"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780100502"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03258.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0833"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709025104"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.12.2688.2688"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.3.687"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0902-4441.2006.t01-1-EJH2879.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0902-4441.2006.t01-1-EJH2879.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:49:04Z","timestamp":1697428144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0902-4441.2006.t01-1-EJH2879.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,24]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1111\/j.0902-4441.2006.t01-1-EJH2879.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0902-4441.2006.t01-1-ejh2879.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2006,7,24]]}}}